Drugs / Diclegis (Registered Trademark)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03905564 Comparator | Jun 2019 → Jun 2020 | — | Grünenthal GmbH | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diclegis (Registered Trademark) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03905564 ↗ |
| Route | Oral | “Oral single dose equivalent to doxylamine succinate 20 mg and pyridoxine hydrochloride 20 mg” NCT03905564 ↗ |